#BEGIN_DRUGCARD DB08887

# AHFS_Codes:
24:06.92

# ATC_Codes:
Not Available

# Absorption:
Icosapent ethyl is de-esterfied, converted into active EPA, and then absorbed in the small intestine. It reaches peak plasma concentration in 5 hours post-oral administration. Very little (<1%) is left circulating in the plasma as EPA incorporates into phospholipids, TG's, and cholesteryl esters.

# Biotransformation:
Once converted into active EPA, it is hepatically metabolized into acetyl Coenzyme A via beta-oxidation.

# Brand_Mixtures:
Not Available

# Brand_Names:
EPAX
Epadel
Vascepa

# CAS_Registry_Number:
86227-47-6

# ChEBI_ID:
Not Available

# Chemical_Formula:
C22H34O2

# Chemical_IUPAC_Name:
ethyl (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate

# Chemical_Structure:
Not Available

# Creation_Date:
2013-05-28 14:35:04 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Icosapent ethyl or ethyl eicosapentaenoic acid is a synthetic derivative of the omega-3 fatty acid eicosapentaenoic acid (EPA). It is used as adjunct therapy for severe hypertriglyceridemia (TG levels > 500 mg/dL). FDA approved on July 26, 2012.

# Dosage_Forms:
Capsule	Oral

# Drug_Category:
Antilipemic Agents

# Drug_Interactions:
Not Available

# Drug_Reference:
23701295	Ballantyne CM, Braeckman RA, Soni PN: Icosapent ethyl for the treatment of hypertriglyceridemia. Expert Opin Pharmacother. 2013 May 24.

# Drug_Type:
Approved
Nutraceutical
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Icosapent ethyl

# HET_ID:
Not Available

# Half_Life:
The half life of EPA is 89 hours.

# InChI_Identifier:
InChI=1/C22H34O2/c1-3-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22(23)24-4-2/h5-6,8-9,11-12,14-15,17-18H,3-4,7,10,13,16,19-21H2,1-2H3/b6-5-,9-8-,12-11-,15-14-,18-17-

# InChI_Key:
InChIKey=SSQPWTVBQMWLSZ-AAQCHOMXNA-N

# Indication:
Icosapent ethyl is used as adjunct therapy to reduce triglyceride (TG) levels in adults with severe (>500 mg/dL) hypertriglyceridemia.

# KEGG_Compound_ID:
C16184

# KEGG_Drug_ID:
D01892

# LIMS_Drug_ID:
8900

# Mechanism_Of_Action:
Studies suggest that EPA reduces hepatic very low-density lipoprotein triglycerides (VLDL-TG) synthesis and/or secretion and enhances TG clearance from circulating VLDL particles. Potential mechanisms of action include increased Î²-oxidation; inhibition of acyl-CoA:1,2-diacylglycerol acyltransferase (DGAT); decreased lipogenesis in the liver; and increased plasma lipoprotein lipase activity.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
330.5042

# Molecular_Weight_Mono:
330.255880332

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
6.8

# Predicted_LogS:
-6.5

# Predicted_Water_Solubility:
9.83e-05 g/l

# Primary_Accession_No:
DB08887

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
Not Available

# PubChem_Substance_ID:
Not Available

# RxList_Link:
http://www.rxlist.com/vascepa-drug.htm

# Salts:
Not Available

# Secondary_Accession_No:
Not Available

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
AMR101
Ethyl Eicosapentaenoate
Ethyl icosapentate
Ethyl-EPA
Ethyl-Eicosapentaenoic Acid

# Synthesis_Reference:
Not Available

# Toxicity:
Icosapent ethyl is generally well tolerated and adverse effects are unrelated to treatment.

# Update_Date:
2013-05-29 00:10:59 -0600

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Ethyl_eicosapentaenoic_acid

# pKa_Isoelectric_Point:
Not Available

#END_DRUGCARD DB08887
